Award
NIH Reporter #5R21CA291683-02
Inhibiting beta-adrenergic and COX-2 signaling during the perioperative period to reduce ovarian cancer progression
Recipient
Tel Aviv University
Award Amount
$137,569.00
Ceiling
$137,569.00
Awarded
August 28, 2025
Identifier
5R21CA291683-02
NIH grant awarded to Tel Aviv University for a clinical trial to reduce ovarian cancer progression by inhibiting beta-adrenergic and COX-2 signaling during the perioperative period using repurposed medications.
Description
This NIH grant supports research on inhibiting beta-adrenergic and COX-2 signaling during the perioperative period to reduce ovarian cancer progression, with a focus on repurposing existing medications like propranolol and etodolac. The project aims to improve long-term outcomes for ovarian cancer patients through a carefully designed clinical trial.